- 18.03.2025 Press release 2024 full-year results
- 20.08.2024 Publication of Medartis 2024 half-year results
- 09.07.2024 Matthias Schupp appointed as CEO of Medartis
- 11.06.2024 Medartis announces resignation of CEO Christoph Brönnimann
- 04.04.2024 Medartis successfully places CHF 115.8 million convertible bonds due 2031
- 03.04.2024 Medartis launches senior convertible bond offering in a private placement
- 12.03.2024 Press release 2023 full-year results
- 15.08.2023 Press release 2023 half-year results
- 17.03.2023 Medartis announces small capital increase
- 16.08.2022 Press release 2022 H1 results
- 03.05.2022 Medartis completes acquisition of Nextremity Solutions Inc. and announces new US leadership
- 14.03.2023 Press release 2022 full-year results
- 08.04.2022 Press release Medartis not to pursue convertible bond placement
- 07.04.2022 Press release Medartis launches convertible bond offering
- 07.03.2022 Press release 2021 fully year results
- 17.08.2021 Press release 2021 H1 results
- 23.04.2021 Press release 2021 annual general meeting
- 09.03.2021 Press release 2020 full-year results
- 11.12.2020 Medartis appoints Dirk Kirsten as Chief Financial Officer and EMB member
- 01.12.2020 Medartis announces strategic partnership with KeriMedical
- 18.08.2020 Press release 2020 half-year results
- 10.06.2020 Medartis appoints Mareike Loch as Vice President EMEA and EMB Member
- 17.04.2020 Press release extension of EMB, Covid-19 and Annual General Meeting 2020
- 18.03.2020 Medartis nominates Marco Gadola for election to the Board of Directors
- 03.03.2020 Medartis announces 2019 results
- 09.12.2019 Medartis provides information on Brazil investigation
- 01.11.2019 Medartis announces change in executive management
- 20.08.2019 Press release 2019 half-year results
- 27.05.2019 Medartis announces Change of CEO as of 1 September 2019
- 10.05.2019 Voting results 2019 Annual General Meeting
- 10.05.2019 Press release 2019 annual general meeting
- 02.04.2019 Press release 2018 full-year results
- 20.02.2019 Medartis announces preliminary key figures for the 2018 financial year
No results
- 18.03.2025 Compensation Report 2024
- 18.03.2025 Recording of the 2024 Full Year Results Conference Call
- 18.03.2025 Annual Report 2024
- 18.03.2025 Presentation 2024 full-year results
- 18.03.2025 Sustainability Report 2024
- 04.02.2025 Invitation Video Webcast: 2024 full year results presentation
- 20.11.2024 Investor's presentation at ZKB and Jefferies conference
- 20.08.2024 Recording of the 2024 Half Year Results Conference Call
- 20.08.2024 Slide presentation of Medartis' half-year results 2024
- 20.08.2024 Half-year report 2024
- 25.07.2024 Invitation Medartis H1 Results 2024
- 17.04.2024 Medartis shareholders approve all proposals at the AGM 2024
- 12.03.2024 Audio Webcast of the 2023 Full Year Results Conference Call
- 12.03.2024 Presentation 2023 full-year results
- 12.03.2024 Corporate Governance Report 2023
- 12.03.2024 Sustainability Report 2023
- 12.03.2024 Remuneration Report 2023
- 12.03.2024 Annual Report 2023
- 22.02.2024 Invitation Audio Webcast: 2023 full year results presentation
- 15.08.2023 Half year Report 2023
- 15.08.2023 Presentation half-year results 2023
- 15.08.2023 Recording of the 2023 Half Year Results Conference Call
- 25.07.2024 Invitation Webcast: Medartis H1 2023 results presentation
- 21.04.2023 Press release 2023 annual general meeting
- 14.03.2023 Recording of the 2022 Full Year Results Conference Call
- 14.03.2023 Presentation 2022 full-year results
- 14.03.2023 Sustainability Report 2022
- 14.03.2023 Remuneration Report 2022
- 14.03.2023 Annual Report 2022
- 16.02.2023 Invitation Webcast: Medartis 2022 full-year results presentation
- 16.08.2022 Recording of telephone conference 2022 half-year results
- 16.08.2022 Presentation half-year results 2022
- 16.08.2022 Financial Report H1 2022
- 27.07.2022 Invitation Webcast: Medartis 2022 half-year results presentation
- 06.04.2022 Press release 2022 annual general meeting
- 07.03.2022 Sustainability at Medartis 2021
- 07.03.2022 Recording of telephone conference 2021 full-year results
- 07.03.2022 Presentation 2021 full-year results
- 07.03.2022 Remuneration Report 2021
- 07.03.2022 Corporate Governance Report 2021
- 07.03.2022 Annual Report 2021
- 17.08.2021 Recording of telephone conference 2021 half-year results
- 17.08.2021 Financial Report H1 2021
- 17.08.2021 Presentation half-year results 2021
- 10.03.2021 Annual Report 2020
- 10.03.2021 Financial Report FY 2020
- 10.03.2021 Remuneration Report 2020
- 10.03.2021 Corporate Governance Report 2020
- 10.03.2021 Recording of telephone conference 2020 full-year results
- 10.03.2021 Presentation 2020 full-year results
No results
- 25.04.2025 Presentation of the CEO at the 2025 Annual General Meeting (only in German)
- 25.04.2025 Voting results 2025 Annual General Meeting (only in German)
- 25.04.2025 Medartis shareholders endorse Board proposals with strong support at AGM 2025
- 18.03.2025 Sustainability Report 2024
- 03.04.2025 Invitation 2025 Annual General Meeting
- 03.04.2025 2024 Annual Report Highlights
- 17.04.2024 Medartis shareholders approve all proposals at the AGM 2024
- 17.04.2024 Voting results 2024 Annual General Meeting (only German)
- 26.03.2024 Invitation 2024 Annual General Meeting
- 26.03.2024 Highlights 2023 Annual Report
- 21.04.2023 Voting results 2023 Annual General Meeting
- 05.04.2023 Changes to the Articles of Association of Medartis Holding AG (German only) – revised
- 30.03.2023 Invitation 2023 Annual General Meeting
- 30.03.2023 Changes to the Articles of Association of Medartis Holding AG (German only) - replaced
- 30.03.2023 Highlights 2022 Annual Report
- 06.04.2022 Voting results 2022 Annual General Meeting
- 15.03.2022 Highlights 2021 Annual Report
- 15.03.2022 Convocation 2022 Annual General Meeting
- 23.04.2021 Voting results 2021 Annual General Meeting
- 29.03.2021 Convocation 2021 Annual General Meeting
- 29.03.2021 Highlights 2020 Annual Report
No results
Key figures full-year 2024
Net sales in CHFm
224.8
Driven by strong performance in EMEA and the US.
Core growth
11.4%
US fastest growing region.
Core EBITDA in CHFm
41.7
EBITDA margin increased from 17% to 19%.
Subscribe to ad hoc-News
Would you like to be informed about Medartis at first hand? Register and receive our news in electronic form.
Do you have any more questions?
Investor Relations:
investor.relations@medartis.com
Phone: +41 61 633 37 36
Media Relations:
corporate.communication@medartis.com
Phone: +41 61 633 37 34
Postal Address:
Medartis AG
Hochbergerstrasse 60E
CH-4057 Basel
Switzerland